[go: up one dir, main page]

WO2002031111A3 - Novel nucleic acids and polypeptides - Google Patents

Novel nucleic acids and polypeptides Download PDF

Info

Publication number
WO2002031111A3
WO2002031111A3 PCT/US2001/027760 US0127760W WO0231111A3 WO 2002031111 A3 WO2002031111 A3 WO 2002031111A3 US 0127760 W US0127760 W US 0127760W WO 0231111 A3 WO0231111 A3 WO 0231111A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/027760
Other languages
French (fr)
Other versions
WO2002031111A2 (en
Inventor
Y Tom Tang
Chenghua Liu
Ping Zhou
Vinod Asundi
Jie Zhang
Qing A Zhao
Feiyan Ren
Aidong J Xue
Yonghong Yang
Tom Wehrman
Radoje T Drmanac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyseq Inc
Original Assignee
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc filed Critical Hyseq Inc
Priority to CA002425827A priority Critical patent/CA2425827A1/en
Priority to EP01977088A priority patent/EP1325120A4/en
Priority to AU2001296235A priority patent/AU2001296235A1/en
Publication of WO2002031111A2 publication Critical patent/WO2002031111A2/en
Publication of WO2002031111A3 publication Critical patent/WO2002031111A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.
PCT/US2001/027760 2000-10-12 2001-10-11 Novel nucleic acids and polypeptides Ceased WO2002031111A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002425827A CA2425827A1 (en) 2000-10-12 2001-10-11 Novel nucleic acids and polypeptides
EP01977088A EP1325120A4 (en) 2000-10-12 2001-10-11 NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2001296235A AU2001296235A1 (en) 2000-10-12 2001-10-11 Novel nucleic acids and polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68752700A 2000-10-12 2000-10-12
US09/687,527 2000-10-12

Publications (2)

Publication Number Publication Date
WO2002031111A2 WO2002031111A2 (en) 2002-04-18
WO2002031111A3 true WO2002031111A3 (en) 2002-10-17

Family

ID=24760764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027760 Ceased WO2002031111A2 (en) 2000-10-12 2001-10-11 Novel nucleic acids and polypeptides

Country Status (4)

Country Link
EP (1) EP1325120A4 (en)
AU (1) AU2001296235A1 (en)
CA (1) CA2425827A1 (en)
WO (1) WO2002031111A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US10663455B2 (en) 2009-09-16 2020-05-26 Active Motif, Inc. Transcription biomarkers of biological responses and methods of use

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
EP2067862A1 (en) * 1999-11-05 2009-06-10 The General Hospital Corporation Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
EP1250434B1 (en) 2000-01-26 2008-04-16 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
JP2002034565A (en) 2000-07-19 2002-02-05 Japan Science & Technology Corp Receptor protein that specifically recognizes bacterial DNA
AU2002211665B2 (en) * 2000-10-12 2005-10-20 Exelixis, Inc. Human Ect2 and methods of use
AU2002210961A1 (en) * 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Novel gene overexpressed in heart and skeletal muscle and use tehreof
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
WO2002057460A2 (en) 2000-12-20 2002-07-25 Bristol-Myers Squibb Company Polynucleotides encoding human phosphatases
US20040132035A1 (en) * 2001-02-07 2004-07-08 Daemen Matthias Joseph A P Markers of unstable atherosclerotic plaques
DK1434592T3 (en) * 2001-04-10 2009-03-09 Agensys Inc Nucleic acid and corresponding protein designated 121P2A3 useful for the treatment and detection of cancer
EP1402058A4 (en) * 2001-06-05 2006-02-01 Exelixis Inc DGK AS MODULATORS OF THE P53 ACTION MECHANISM AND METHODS OF USE
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2003024080A (en) * 2001-07-19 2003-01-28 Univ Tokyo Screening method for p53-dependent apoptosis-inducing protein and apoptosis regulator
AU2003281314A1 (en) * 2002-07-09 2004-01-23 Takeda Pharmaceutical Company Limited Nove protein and use thereof
JP4301541B2 (en) * 2002-09-05 2009-07-22 独立行政法人科学技術振興機構 Screening method of SMG-1 binding protein and substance controlling its activity
JP2006521082A (en) * 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
WO2004042386A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a3 (pde11a3)
AU2003901055A0 (en) * 2003-02-17 2003-03-20 Nathan E Hall Methods for inhibiting signal transduction
EP1627051A4 (en) * 2003-05-07 2006-09-06 Univ Massachusetts REGULATION OF ACHERON EXPRESSION
EP1636384A4 (en) * 2003-06-20 2007-03-07 Amgen Inc GENE AMPLIFICATION AND OVEREXPRESSION IN CANCER
WO2005014817A2 (en) * 2003-08-07 2005-02-17 Compugen Ltd. Chordin-like homologs
EP1687330A4 (en) * 2003-10-28 2007-03-14 Protemix Discovery Ltd Peptides with anti-obesity activity and other related uses
CA2555469A1 (en) 2004-02-09 2005-08-18 Eisai R & D Management Co., Ltd. Use of relaxin-3 for promoting food intake, increasing body weight gain, increasing fat weight and for others
JP2007522791A (en) * 2004-02-24 2007-08-16 オンコセラピー・サイエンス株式会社 How to diagnose colorectal cancer
JP4712692B2 (en) * 2004-06-02 2011-06-29 Ｔｓｓバイオテック株式会社 Novel polypeptides useful in cancer diagnosis and treatment
US7741299B2 (en) 2004-08-16 2010-06-22 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
US7531634B2 (en) * 2004-12-03 2009-05-12 University Of Pittsburgh Bladder matrix protein peptides and methods of detection of bladder cancer
EP2311983A1 (en) * 2005-02-10 2011-04-20 Oncotherapy Science, Inc. Method of treating bladder cancer using siRNA
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
WO2006115295A1 (en) * 2005-04-25 2006-11-02 University Of Yamanashi Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
NL2000439C2 (en) 2006-01-20 2009-03-16 Quark Biotech Therapeutic applications of inhibitors of RTP801.
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
KR101493773B1 (en) 2006-10-17 2015-03-03 온코세라피 사이언스 가부시키가이샤 Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
JP2010518880A (en) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Inhibitors of RTP801 and their use in the treatment of diseases
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
CA2732142A1 (en) * 2008-07-28 2010-02-04 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
WO2010023850A1 (en) 2008-08-28 2010-03-04 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the depdc1 polypeptide
RU2600888C2 (en) 2009-03-18 2016-10-27 Онкотерапи Сайенс, Инк. Neil3 peptides and vaccines including same
GB201009654D0 (en) * 2010-06-09 2010-07-21 Cancer Res Technology Nucleic acid methyltransferase
TWI467016B (en) * 2011-08-31 2015-01-01 Taipei Veteran General Hospital Gene delivery of oct4 and sirt1 and pharmaceutical compositions thereof
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
US10676508B2 (en) 2015-08-12 2020-06-09 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2025053123A1 (en) * 2023-09-04 2025-03-13 国立研究開発法人理化学研究所 Method for improving mitochondrial function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508088A (en) * 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 52 human secreted proteins
ES2484966T3 (en) * 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Albumin fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Random primers DNA labeling system", GIBCO BRL CATALOGUE AND REFERENCE GUIDE, LIFE TECHNOLOGIES, INC., 1990, GAITHERSBURG, MD 20877, USA, pages 404, XP002950899 *
See also references of EP1325120A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response
US10663455B2 (en) 2009-09-16 2020-05-26 Active Motif, Inc. Transcription biomarkers of biological responses and methods of use

Also Published As

Publication number Publication date
WO2002031111A2 (en) 2002-04-18
CA2425827A1 (en) 2002-04-18
EP1325120A4 (en) 2005-05-25
EP1325120A2 (en) 2003-07-09
AU2001296235A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2004009834A3 (en) Novel nucleic acids and secreted polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2003080795A8 (en) Novel nucleic acids and secreted polypeptides
WO2005049806A3 (en) Novel nucleic acids and polypeptides
WO2001002571A3 (en) An interleukin-1 receptor antagonist and uses thereof
WO2002044340A3 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2425827

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001977088

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001977088

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001977088

Country of ref document: EP